• Cognition Therapeutics posted a new press release announcing CEO Lisa Ricciardi will join a fireside chat at B. Riley’s Mind, Muscle & Vision Summit.
• The July 16, 2026 session will cover the ongoing Phase 2 START study, plans to launch a Phase 3 registrational trial of zervimesine (CT1812) in DLB psychosis.
• A replay is expected to be available on the company’s investor relations site at https://cogrx.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130730PRIMZONEFULLFEED9760503) on July 13, 2026, and is solely responsible for the information contained therein.